https://orcid.org/0000-0001-7809-2580
References
- Levin A , TonelliM, BonventreJet al. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet390(10105), 1888–1917 (2017).
- Zhang L , WangF, WangLet al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet379(9818), 815–822 (2012).
- Haas M , MoolenaarF, MeijerDKF, de ZeeuwD. Specific drug delivery to the kidney. Cardiovasc. Drugs. Ther.16(6), 489–496 (2002).
- Liu CP , HuY, LinJC, FuHL, LimLY, YuanZX. Targeting strategies for drug delivery to the kidney: from renal glomeruli to tubules. Med. Res. Rev.39(2), 561–578 (2019).
- Scindia YM , DeshmukhUS, BagavantH. Mesangial pathology in glomerular disease: targets for therapeutic intervention. Adv. Drug Delivery Rev.62(14), 1337–1343 (2010).
- Choi CHJ , ZuckermanJE, WebsterP, DavisME. Targeting kidney mesangium by nanoparticles of defined size. Proc. Natl Acad. Sci. USA108(16), 6656–6661 (2011).
- Guo L , LuoS, DuZet al. Targeted delivery of celastrol to mesangial cells is effective against mesangioproliferative glomerulonephritis. Nat. Commun.8(1), 878 (2017).
- Yuan ZX , JiaL, LimLYet al. Renal-targeted delivery of triptolide by entrapment in pegylated TRX-20-modified liposomes. Int. J. Nanomed.12, 5673–5686 (2017).
- Tuffin G , WaeltiE, HuwylerJ, HammerC, MartiHP. Immunoliposome targeting to mesangial cells: a promising strategy for specific drug delivery to the kidney. J. Am. Soc. Nephrol.16(11), 3295–3305 (2005).
- Bruni R , PossentiP, BordignonCet al. Ultrasmall polymeric nanocarriers for drug delivery to podocytes in kidney glomerulus. J. Control. Rel.255, 94–107 (2017).
- Wang J , PoonC, ChinDet al. Design and in vivo characterization of kidney-targeting multimodal micelles for renal drug delivery. Nano Res.11(10), 5584–5595 (2018).
- Yamashita F , HashidaM. Pharmacokinetic considerations for targeted drug delivery. Adv. Drug Delivery Rev.65(1), 139–147 (2013).
- Zhang Z , ZhengQ, HanJet al. The targeting of 14-succinate triptolide-lysozyme conjugate to proximal renal tubular epithelial cells. Biomaterials30(7), 1372–1381 (2009).
- He XK , YuanZX, WuXJ, XuCQ, LiWY. Low molecular weight hydroxyethyl chitosan-prednisolone conjugate for renal targeting therapy: synthesis, characterization and in vivo studies. Theranostics2(11), 1054–1063 (2012).
- Matsuura S , KatsumiH, SuzukiHet al. L-Serine-modified polyamidoamine dendrimer as a highly potent renal targeting drug carrier. Proc. Natl Acad. Sci. USA115(41), 10511–10516 (2018).
- Yamamoto Y , TsutsumiY, YoshiokaYet al. Poly(vinylpyrrolidone-co-dimethyl maleic acid) as a novel renal targeting carrier. J. Control. Rel.95(2), 229–237 (2004).
- Kurts C , PanzerU, AndersHJ, ReesAJ. The immune system and kidney disease: basic concepts and clinical implications. Nat. Rev. Immunol.13(10), 738–753 (2013).
- Drieman JC , ThijssenHHW, Struyker-BoudierHAJ. Renal selective N-acetyl-l-γ-glutamyl prodrugs: studies on the selectivity of some model prodrugs. Br. J. Pharmacol.108(1), 204–208 (1993).
- Wang S , LuoJ, LantripDAet al. Design and synthesis of [111In]DTPA-folate for use as a tumor-targeted radiopharmaceutical. Bioconjugate Chem.8(5), 673–679 (1997).
- Lin Y , LiY, WangX, GongT, ZhangL, SunX. Targeted drug delivery to renal proximal tubule epithelial cells mediated by 2-glucosamine. J. Control. Rel.167(2), 148–156 (2013).